Pancreatic Cancer Clinical Trials
Category:Adult
Status:Active
Displaying all 18 trials
The purpose of this study is to compare the efficacy and safety of PEGylated Recombinant Human Hyaluronidase (PEGPH20) combined with nab-paclitaxel plus gemcitabine (PAG treatment), compared with p...
Diagnosis: Gastrointestinal Malignancies, Pancreatic Cancer
Phase: 3
Protocol Number: 16-146
Hospitalized patients with pancreatic, stomach, ovarian or non-small lung cancer, or non-Hodgkin's lymphoma and who are at high risk for a venous thromboembolisn will be randomized to standard ...
Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer, Other Cancers, Stomach Cancer, Non-Hodgkin's Lymphoma, Pancreatic Cancer
Phase: 2
Protocol Number: 15-547
Gemcitabine Plus BPM31510 Administered Intravenously in Advanced Pancreatic Cancer Patients
This is a Phase 2 multicenter, open-label, non-randomized study to examine the safety and effectiveness of the combination of BPM31510 administered as a 144-hour continuous intravenous (IV) infusio...
Diagnosis: Pancreatic Cancer, Gastrointestinal Malignancies
Phase: 2
Protocol Number: 17-066
Safety and Efficacy of FGF401 in Patients With Solid Malignancies
Estimate the maximum tolerated dose and/or recommended phase two dose and efficacy of FGF401 on patients with solid malignancies
Diagnosis: Gastrointestinal Malignancies, Stomach Cancer, Liver Cancer, Colorectal Cancer, Pancreatic Cancer, Esophageal Cancer
Phase: 1 / 2
Protocol Number: 14-464
A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Pr...
Diagnosis: Pancreatic Cancer, Gastrointestinal Malignancies
Phase:
Protocol Number: 15-191
Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy
This research study is looking at people with cancer of the pancreas to find clinical factors that can explain the presence of genetic mutations
Diagnosis: Pancreatic Cancer
Phase:
Protocol Number: 16-448
The purpose of this clinical trial is to study an experimental drug called pembrolizumab or MK-3475 for use in combination with chemotherapy and radiation therapy for patients with resectable (surg...
Diagnosis: Gastrointestinal Malignancies, Pancreatic Cancer
Phase:
Protocol Number: 16-490
Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer
This research study is studying a combination of drugs with radiation therapy as a possible treatment for Microsatellite Stable Colorectal Cancer, Pancreatic Cancer, or MSI High Colorectal Cancer. ...
Diagnosis: Colorectal Cancer, Pancreatic Cancer
Phase:
Protocol Number: 17-021
Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies
The purpose of this study of MCS110 with PDR001 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the combination of MCS110 with P...
Diagnosis: GYN: Endometrial/Uterine Cancer, Melanoma, Pancreatic Cancer, Breast: Early Stage Disease
Phase:
Protocol Number: 16-491
The objective of this study is to estimate the R0 resection rate in patients with Resectable Pancreatic Ductal Adenocarcinoma (R-PDAC) as well as those with Resectable Pancreatic Ductal Adenocarcin...
Diagnosis: Pancreatic Cancer
Phase:
Protocol Number: 17-326
Physical Activity In Gastrointestinal Cancer
This research study is evaluating the ability for people with metastatic gastrointestinal cancer to participate in a physical activity program.
Diagnosis: Pancreatic Cancer, Colorectal Cancer, Gastrointestinal Malignancies, Esophageal Cancer
Phase:
Protocol Number: 17-350
To identify the maximally tolerated dose of ficlatuzumab when combined with nab-paclitaxel and gemcitabine in patients with previously untreated pancreatic cancer.
Diagnosis: Gastrointestinal Malignancies, Pancreatic Cancer
Phase:
Protocol Number: 17-406
A Phase Ib/II, open-label, multicenter, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinati...
Diagnosis: Gastrointestinal Malignancies, Pancreatic Cancer
Phase:
Protocol Number: 17-429
To improve progression free survival in high risk patients with resected pancreatic adenocarcinoma who have node positive disease, margin positive disease, and/or elevation in CA 19-9 treated with ...
Diagnosis: Pancreatic Cancer, Gastrointestinal Malignancies
Phase:
Protocol Number: 17-169
This research study is evaluating a study drug to treat pancreatic exocrine insufficiency (PEI) during the first year after the diagnosis of pancreatic cancer while the participant is recovering fr...
Diagnosis: Gastrointestinal Malignancies, Pancreatic Cancer
Phase:
Protocol Number: 17-450
This phase II trial studies how well selumetinib sulfate works in treating patients with pancreatic cancer with KRAS G12R mutations that has spread from where it started to nearby tissue or lymph n...
Diagnosis: Pancreatic Cancer, Gastrointestinal Malignancies
Phase:
Protocol Number: 18-710
RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer
This will be a Phase 1a/2b multicenter 2-stage study. Phase 1 will be conducted as a dose-finding, open-label study of oral RX-3117 administered in combination with Abraxane® to subjects with metas...
Diagnosis: Gastrointestinal Malignancies, Pancreatic Cancer
Phase:
Protocol Number: 17-665
The GI Binder: A Psychoeducational Intervention for Pancreatic Cancer Patients
This research study is evaluating the use of a binder of educational materials with nurse teaching to prepare patients for chemotherapy
Diagnosis: Pancreatic Cancer
Phase:
Protocol Number: 18-241
